Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 6/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | AXL | P30530 | 1/20 | 0.50 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.50 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.50 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.50 |
| ▸ | CYP2E1 | P05181 | 3/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.49 |
| ▸ | CYP2B6 | P20813 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.44 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2546824 | 0.76 | LMNA (0.42) | CYP3A4CYP19A1ALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL1424931 | 0.70 | KDM4E (0.75) | CYP2A6CYP3A4CYP19A1ALDH1A1CYP1A2 | |
| SCHEMBL30473120 | 0.70 | CYP2A6 (1.00) | CYP2A6CYP3A4CYP19A1ALDH1A1CYP1A2 | |
| SCHEMBL120088 | 0.70 | CYP2A6 (1.00) | CYP2A6CYP3A4CYP19A1ALDH1A1CYP1A2 | |
| SCHEMBL29419014 | 0.70 | CYP2A6 (1.00) | CYP2A6CYP3A4CYP19A1ALDH1A1CYP1A2 | |
| SCHEMBL252650 | 0.69 | CYP2A6 (1.00) | CYP2A6CYP3A4CYP19A1ALDH1A1CYP1A2 | |
| SCHEMBL29381812 | 0.69 | CYP2A6 (1.00) | CYP2A6CYP3A4CYP19A1ALDH1A1CYP1A2 | |
| SCHEMBL7510817 | 0.69 | RAB9A (0.44) | CYP19A1ALDH1A1CYP1A2KDM4ERAB9A | |
| SCHEMBL1680218 | 0.68 | CYP2A6 (0.55) | CYP2A6CYP3A4CYP19A1ALDH1A1CYP1A2 | |
| SCHEMBL2649865 | 0.68 | DYRK1A (0.55) | CYP2A6CYP3A4CYP19A1ALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 153 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9962377-B2 | Hydroxy-6-heteroarylphenanthridines and their use as PDE4 inhibitors | TAKEDA GMBH (DE) | 2018-05-08 | — | — | US | claimed |
| EP-2200440-B1 | ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS | CRESTONE INC (US) | 2017-07-19 | — | — | EP | claimed |
| US-20160279120-A1 | NOVEL HYDROXY-6-HETEROARYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS | TAKEDA GMBH (DE) | 2016-09-29 | — | — | US | claimed |
| CN-104817534-A | Novel hydroxy-6-heteroarylphenanthridines and their use as PDE4 inhibitors | ALTANA PHARMA AG | 2015-08-05 | — | — | CN | claimed |
| US-8883818-B2 | Hydroxy-6-heteroarylphenanthridines and their use as PDE4 inhibitors | TAKEDA GMBH (DE) | 2014-11-11 | — | — | US | claimed |
| US-20140073636-A1 | NOVEL HYDROXY-6-HETEROARYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS | TAKEDA GMBH (DE) | 2014-03-13 | — | — | US | claimed |
| EP-1723135-B1 | NOVEL HYDROXY-6-HEROARYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS | TAKEDA GMBH (DE) | 2013-06-19 | — | — | EP | claimed |
| US-8455653-B2 | Hydroxy-6-heteroarylphenanthridines and their use as PDE4 inhibitors | TAKEDA GMBH (DE) | 2013-06-04 | — | — | US | claimed |
| US-20130045974-A1 | NOVEL HYDROXY-6-HETEROARYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS | NYCOMED GMBH (DE) | 2013-02-21 | — | — | US | claimed |
| US-8318944-B2 | Hydroxy-6-heteroarylphenanthridines and their use as PDE4 inhibitors | NYCOMED GMBH (DE) | 2012-11-27 | — | — | US | claimed |
| US-6376538-B1 | ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASES | BIOGEN, INC. | 2002-04-23 | — | — | US | claimed |
| US-20020035103-A1 | 1,3-Disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications | ABBVIE INC. | 2002-03-21 | — | — | US | claimed |
| WO-2002014311-A2 | UREA COMPOUNDS AND METHODS OF USES | AMGEN INC. (US) | 2002-02-21 | — | — | WO | claimed |
| EP-1180110-A1 | 13-METHYL-ERYTHROMYCIN DERIVATIVES | Pfizer Products Inc. (US) | 2002-02-20 | — | — | EP | claimed |
| WO-2002006223-A1 | 1,3-DISUBSTITUTED AND 1,3,3-TRISUBSTITUTED PYRROLIDINES AS HISTAMINE-3 RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | ABBOTT LABORATORIES (US) | 2002-01-24 | — | — | WO | claimed |
| EP-1146051-A2 | Erythromycin A derivatives | Pfizer Products Inc. (US) | 2001-10-17 | — | — | EP | claimed |
| WO-2000071557-A1 | 13-METHYL-ERYTHROMYCIN DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2000-11-30 | — | — | WO | claimed |
| EP-0805796-A1 | CELL ADHESION INHIBITORS | BIOGEN, INC. (US) | 1997-11-12 | — | — | EP | claimed |
| WO-1996022966-A1 | CELL ADHESION INHIBITORS | BIOGEN, INC. (US) | 1996-08-01 | — | — | WO | claimed |
| US-5470862-A | Intravenous anesthetics | OHMEDA PHARMACEUTICAL PRODUCTS DIVISION INC. (US) | 1995-11-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035103-A1 | 1,3-Disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications | HRH3, HRH4, HRH1 | CYP2A6 2564/4885CYP3A4 2475/4885CYP19A1 2839/4885 |
| US-20140073636-A1 | NOVEL HYDROXY-6-HETEROARYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS | PDE4A, PDE4B, PDE12 | CYP2A6 53/4885CYP3A4 26/4885CYP19A1 150/4885 |
| US-20130045974-A1 | NOVEL HYDROXY-6-HETEROARYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS | PDE4A, PDE4B, PDE4C | CYP2A6 63/4885CYP3A4 31/4885CYP19A1 782/4885 |
| US-20160279120-A1 | NOVEL HYDROXY-6-HETEROARYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS | PDE4A, PDE12, PDE4B | CYP2A6 38/4885CYP3A4 24/4885CYP19A1 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.